Friday, June 19, 2026
🇺🇸 FDA

pharma · Hereditary Angioedema · Influenza · BCRX

Biocryst

Biocryst clinical programs — 37 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
München, DE HQ
1986 Founded
6 Employees
Public company Type
BCRX · NYSE Ticker
Company details
Status
Public
HQ
München, DE
Founded
1986
Employees
6
Programs
37
Drugs
17
Patents
72
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Biocryst projects

37 ClinicalTrials.gov programs sponsored by Biocryst.

Biocryst has 37 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

37 programs

Clinical programs

  1. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  2. BCX7353

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  3. BCX7353 capsules

    Biocryst

    Hereditary Angioedema, HAE

    phase 3 small molecule completed

    1 trial

  4. BCX7353 capsules

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  5. Peramivir

    Biocryst

    Influenza

    phase 3 small molecule completed

    5 trials

  6. Peramivir

    Biocryst

    Seasonal Influenza

    phase 3 small molecule completed

    1 trial

  7. Peramivir 150mg

    Biocryst

    Influenza

    phase 3 small molecule terminated

    1 trial

  8. Peramivir+SOC

    Biocryst

    Cough

    phase 3 small molecule terminated

    1 trial

  9. avoralstat

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule terminated

    1 trial

  10. berotralstat

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule active

    2 trials

  11. BCX-1777

    Biocryst

    Leukemia, Lymphocytic

    phase 2 small molecule completed

    1 trial

  12. BCX1777-Tio-05-202

    Biocryst

    Leukemia

    phase 2 small molecule terminated

    1 trial

  13. BCX7353

    Biocryst

    Hereditary Angioedema (HAE)

    phase 2 small molecule completed

    2 trials

  14. BCX9930

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule terminated

    3 trials

  15. BCX9930

    Biocryst

    Complement 3 Glomerulopathy

    phase 2 small molecule terminated

    1 trial

  16. Eculizumab

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule terminated

    1 trial

  17. Forodesine 200 mg

    Biocryst

    Cutaneous T-cell Lymphoma (CTCL),

    phase 2 small molecule completed

    1 trial

  18. Peramivir

    Biocryst

    Acute, Uncomplicated Human Influenza

    phase 2 small molecule completed

    1 trial

  19. Peramivir 150 mg

    Biocryst

    Influenza

    phase 2 small molecule completed

    1 trial

  20. Peramivir 200 mg

    Biocryst

    Influenza

    phase 2 small molecule completed

    1 trial

  21. Placebo

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule terminated

    1 trial

  22. Placebo

    Biocryst

    Gout

    phase 2 small molecule completed

    3 trials

  23. forodesine HCl

    Biocryst

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  24. forodesine hydrochloride

    Biocryst

    Lymphoma

    phase 2 small molecule completed

    2 trials

  25. forodesine hydrochloride (BCX-1777)

    Biocryst

    Leukemia, Lymphocytic, Chronic

    phase 2 small molecule completed

    1 trial

  26. forodesine hydrochloride (BCX-1777)

    Biocryst

    Leukemia, T-Cell

    phase 2 small molecule completed

    1 trial

  27. forodesine hydrochloride (BCX-1777)

    Biocryst

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

  28. ulodesine

    Biocryst

    Gout

    phase 2 small molecule completed

    1 trial

  29. BCX10013

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 1 small molecule completed

    1 trial

  30. BCX17725

    Biocryst

    Netherton Syndrome

    phase 1 small molecule active

    1 trial

  31. BCX4430

    Biocryst

    Filovirus Infections

    phase 1 small molecule completed

    1 trial

  32. BCX7353 and probes

    Biocryst

    Hereditary Angioedema

    phase 1 small molecule completed

    1 trial

  33. Galidesivir

    Biocryst

    COVID-19

    phase 1 small molecule terminated

    1 trial

  34. Peldesine

    Biocryst

    HIV Infections

    phase 1 small molecule completed

    1 trial

  35. avoralstat

    Biocryst

    Diabetic Macular Edema (DME)

    phase 1 small molecule terminated

    1 trial

  36. forodesine hydrochloride

    Biocryst

    Cancer

    phase 1 small molecule completed

    1 trial

  37. galidesivir

    Biocryst

    Marburg Virus Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Biocryst have?

37 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.